RSV Disease: Current Management and the Future of Treatment and Prevention

• Type of Material: Article
• Authors: Leonard R. Krilov, NYU Langone Hospital Long Island; Joseph B. Domachowske, SUNY Upstate Medical University; Evan Anderson, Emory University
• Language: English
• Date: 2021-03-03
• Publisher: Springer London Ltd.
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2021
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1007/s40121-020-00386-3
• Title of Journal or Parent Work: Infectious Diseases and Therapy
• Volume: 10
• Issue: SUPPL 1
• Start Page: 1
• End Page: 3
• Grant/Funding Information: This study and the Rapid Service Fees were sponsored by Sobi, Inc.
• Keywords: Treatments; Prevention or Immunoprophylaxis; Respiratory syncytial virus hospitalizations; Palivizumab; Respiratory syncytial virus; Cost; Infectious Diseases; Epidemiology; American Academy of Pediatrics; Life Sciences & Biomedicine; Science & Technology
• Research Categories: Health Sciences, Immunology; Health Sciences, Epidemiology; Health Sciences, Medicine and Surgery

Abstract

Since the initial discovery of respiratory syncytial virus (RSV) in 1956 and its association with infant bronchiolitis, much has been learned about the epidemiology and clinical manifestations of RSV infection [1, 2]. Despite these developments, effective treatments are lacking [3]. Immunoprophylaxis (IP) with the humanized monoclonal antibody palivizumab has been available since 1998 and is highly effective [reducing RSV hospitalization (RSVH) rates up to 78% and preventing RSVH by 58% in high-risk pediatric populations] [3–7]. However, due to cost concerns and controversy surrounding the optimal patient populations for such IP, its use is limited to high-risk infants and children [3].